Compounds > atazanavir sulfate
Page last updated: 2024-09-04

atazanavir sulfate and Acquired Immune Deficiency Syndrome

atazanavir sulfate has been researched along with Acquired Immune Deficiency Syndrome in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (30.00)29.6817
2010's14 (70.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abgrall, S; Arribas, JR; Barger, D; Barrufet, P; Braun, D; Caniglia, EC; Cardoso, SW; Chrysos, G; Costagliola, D; Gill, J; Gogos, C; Hauser, C; Hernán, MA; Hoyos, SP; Justice, A; Leyes, M; Lodi, S; Logan, R; Meyer, L; Moreno, S; Muga, R; Pacheco, A; Phillips, A; Porter, K; Reiss, P; Sabin, CA; Seng, R; Tate, J; van Sighem, A; Vandenhende, MA; Winston, A1
Hunt, PW; Lim, J; McComsey, GA; Messing, S; Morse, GD; Venuto, CS1
Alobwede, SM; Kongnyuy, EJ; Shey, MS; Wiysonge, CS1
Daar, ES; Haas, DW; Johnson, DH; McLaren, PJ; Morse, GD; Ritchie, MD; Venuto, C1
Alnouti, Y; Bade, AN; Dash, PK; Edagwa, B; Gautam, N; Gelbard, HA; Gendelman, HE; Gnanadhas, DP; Gorantla, S; Lin, Z; McMillan, J; Mosley, RL; Palandri, DL; Sillman, B1
Kongnyuy, EJ; Shang, J; Shey, M; Wiysonge, CS1
Honda, M; Ishisaka, M; Ishizuka, N; Kimura, S; Oka, S1
Agnes, G; Basso, RP; de Almeida, S; Kuhmmer, R; Lazzaretti, RK; Mattevi, VS; Pinheiro, CA; Ribeiro, JP; Silveira, JM; Silveira, MF; Sprinz, E; Turatti, L1
Ballell, L; Garcia-Bennett, AE; Xia, X; Zhou, C1
Deeks, ED1
Aberg, JA; De La Rosa, G; Falcon, R; Gupta, SK; Landay, A; Overton, ET; Ryan, R; Sax, PE; Tebas, P1
Anderson, PL; Aquilante, CL; Castillo-Mancilla, JR; Kile, DA; MaWhinney, S; Rower, JE1
Butcher, D; Farajallah, A; Hu, W; Juethner, S; McDonald, C; McGrath, D; Moyle, G; Uy, J; Wirtz, V1
Bloom, A; Brown, TT; Daar, ES; Fedarko, N; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C1
Gallant, JE1
Laurence, J1
Antoniou, T; Beique, L; Chirhin, S; Gough, K; Loutfy, MR; Rachlis, A; Yoong, D1
Colson, P; Lacarelle, B; Moreau, J; Poizot-Martin, I; Ravaux, I; Solas, C; Tamalet, C1

Reviews

4 review(s) available for atazanavir sulfate and Acquired Immune Deficiency Syndrome

ArticleYear
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
    The Cochrane database of systematic reviews, 2013, Mar-28, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine

2013
A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine

2009
Atazanavir: in pediatric patients with HIV-1 infection.
    Paediatric drugs, 2012, Apr-01, Volume: 14, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Area Under Curve; Atazanavir Sulfate; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult

2012
HIV therapeutics, continued: another HIV protease inhibitor approved.
    The AIDS reader, 2003, Volume: 13, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Approval; Drug Resistance, Viral; Headache; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Hypercholesterolemia; Nausea; Oligopeptides; Patient Selection; Pyridines; Treatment Outcome; United States; United States Food and Drug Administration; Viral Load

2003

Trials

7 trial(s) available for atazanavir sulfate and Acquired Immune Deficiency Syndrome

ArticleYear
Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
    Antiviral therapy, 2018, Volume: 23, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adult; Atazanavir Sulfate; Biomarkers; Female; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Male; Treatment Outcome

2018
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
    Pharmacogenetics and genomics, 2014, Volume: 24, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Female; Genome-Wide Association Study; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polymorphism, Single Nucleotide; Prospective Studies; Pyridines; Ritonavir

2014
[Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
    MMW Fortschritte der Medizin, 2014, Jun-12, Volume: 156 Suppl 1

    Topics: Acquired Immunodeficiency Syndrome; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides

2014
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:7

    Topics: Acquired Immunodeficiency Syndrome; Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cholesterol; Cyclopropanes; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Japan; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome

2011
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:10

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Atazanavir Sulfate; Biomarkers; CD4 Lymphocyte Count; Darunavir; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Viral Load; Young Adult

2012
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
    AIDS patient care and STDs, 2012, Volume: 26, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV-1; Humans; Hyperbilirubinemia; Lopinavir; Male; Medication Adherence; Oligopeptides; Pyridines; Quality of Life; Ritonavir; Surveys and Questionnaires

2012
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
    AIDS (London, England), 2012, Jul-17, Volume: 26, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; C-Reactive Protein; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV-1; Humans; Inflammation; Interleukin-6; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tumor Necrosis Factor-alpha

2012

Other Studies

9 other study(ies) available for atazanavir sulfate and Acquired Immune Deficiency Syndrome

ArticleYear
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.
    Journal of acquired immune deficiency syndromes (1999), 2018, 01-01, Volume: 77, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Alkynes; Americas; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Darunavir; Europe; Female; HIV Protease Inhibitors; Humans; Leukoencephalopathy, Progressive Multifocal; Lopinavir; Male; Meningitis, Cryptococcal; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Toxoplasmosis

2018
Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.
    The Journal of clinical investigation, 2017, Mar-01, Volume: 127, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Female; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Macrophages; Male; Mice; Nanoparticles; Oxazines; Piperazines; Pyridines; Pyridones; Pyrroles

2017
Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Adult; Alleles; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Brazil; Cross-Sectional Studies; Female; Genotype; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Indinavir; Male; Oligopeptides; Predictive Value of Tests; Pyridines; Risk Factors; Severity of Illness Index

2012
In vivo enhancement in bioavailability of atazanavir in the presence of proton-pump inhibitors using mesoporous materials.
    ChemMedChem, 2012, Jan-02, Volume: 7, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Atazanavir Sulfate; Drug Carriers; Humans; Oligopeptides; Porosity; Proton Pump Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Silicon Dioxide; Solubility

2012
A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:10

    Topics: Acquired Immunodeficiency Syndrome; Adult; Atazanavir Sulfate; Black or African American; Cost-Benefit Analysis; Cytochrome P-450 CYP3A; Female; Genotype; Haplotypes; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyridines; Ritonavir; Treatment Outcome; White People; Young Adult

2012
New antiretroviral agents.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 2001, Volume: 13, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Deoxycytidine; Dioxolanes; Drugs, Investigational; Emtricitabine; Furans; Guanosine; HIV Fusion Inhibitors; Humans; Imidazoles; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Prodrugs; Protease Inhibitors; Pyridines; Pyrones; Quinazolines; Reverse Transcriptase Inhibitors; Sulfonamides; Sulfur Compounds; Tenofovir

2001
["Once daily" drugs simplify therapy. Rp. HAART once daily].
    MMW Fortschritte der Medizin, 2003, Apr-28, Volume: 145 Spec No 1

    Topics: Acquired Immunodeficiency Syndrome; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Humans; Oligopeptides; Oxazines; Patient Compliance; Pyridines; Treatment Outcome

2003
Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series.
    Journal of acquired immune deficiency syndromes (1999), 2005, May-01, Volume: 39, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antacids; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies

2005
The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients.
    Journal of acquired immune deficiency syndromes (1999), 2008, Jun-01, Volume: 48, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Oligopeptides; Pyridines

2008